By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Cadence
Pharmaceuticals, Inc. et al. v. Sandoz Inc.
3:13-cv-00733;
filed February 5, 2013 in the District Court of New Jersey

• Plaintiffs: 
Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendant: 
Sandoz Inc.

Cadence
Pharmaceuticals, Inc. et al. v. Sandoz, Inc.
3:13-cv-00278;
filed February 4, 2013 in the Southern District of California

• Plaintiffs: 
Cadence Pharmaceuticals, Inc.; SCR Pharmatop
• Defendant: 
Sandoz, Inc.

The
complaints in these cases are substantially identical.  Infringement of U.S. Patent Nos. 6,028,222 ("Stable
Liquid Paracetamol Compositions, and Method for Preparing the Same,"
issued February 22, 2000) and 6,992,218 ("Method for Obtaining Aqueous
Formulations of Oxidation-Sensitive Active Principles," issued January 31,
2006), both licensed to Cadence, following a Paragraph IV certification as part
of Sandoz's filing of an ANDA to manufacture a generic version of Cadence's
Ofirmev® (acetaminophen injection, used for the management of mild to moderate
pain, the management of moderate to severe pain with adjunctive opioid
analgesics, and the reduction of fevers). 
View the SD California complaint here.

Purdue Pharma
L.P. et al. v. Watson Laboratories, Inc. et al.
1:13-cv-00762;
filed February 4, 2013 in the Southern District of New York

• Plaintiffs: 
Purdue Pharma L.P.; Grunenthal GmbH
• Defendants: 
Watson Laboratories, Inc.; Andrx Labs, L.L.C.

Infringement
of U.S. Patent No. 8,309,060 ("Abuse-Proofed Dosage Form," issued
November 13, 2012) following a Paragraph IV certification as part of Watson's
filing of an ANDA to manufacture a generic version of Purdue Pharma's
OxyContin® (controlled release oxycodone hydrochloride, used to treat
pain).  View the complaint here.

Purdue Pharma
L.P. et al. v. IMPAX Laboratories, Inc.
1:13-cv-00763;
filed February 1, 2013 in the Southern District of New York

• Plaintiffs: 
Purdue Pharma L.P.; Grunenthal GmbH
• Defendant: 
IMPAX Laboratories, Inc.

Infringement
of U.S. Patent Nos. 8,114,383 ("Abuse-Proofed Dosage Form," issued
February 14, 2012) and 8,309,060 (same title, issued November 13, 2012)
following a Paragraph IV certification as part of Impax's filing of an ANDA to
manufacture a generic version of Purdue Pharma's OxyContin® (controlled release
oxycodone hydrochloride, used to treat pain). 
View the complaint here.

Merck Sharp
& Dohme Corp. et al. v. APP Pharmaceuticals Inc. et al.
1:13-cv-00166;
filed January 31, 2013 in the District Court of Delaware

• Plaintiffs: 
Merck Sharp & Dohme Corp.; Millennium Pharmaceuticals Inc.
• Defendants: 
APP Pharmaceuticals Inc.; APP Pharmaceuticals LLC; Fresenius Kabi
Pharmaceuticals Holding Inc.; Fresenius Kabi USA Inc.; Fresenius Kabi USA
LLC

Infringement
of U.S. Patent Nos. 5,807,825 ("Platelet Aggregation Inhibitors,"
issued September 15, 1998), 5,747,447 ("Stable Polypeptide Composition,"
issued May 5, 1998) and 5,968,902 ("Platelet Aggregation Inhibitors,"
issued October 19, 1999), licensed to Merck, following a Paragraph IV
certification as part of APP's filing of an amendment to their ANDA (adding an
additional dosage form) to manufacture a generic version of Merck's Integrilin®
(eptifibatide injection, used to treat acute coronary syndrome).  View the complaint here.